Healthcare Industry News: collagen scaffold
News Release - April 20, 2009
U.S. Surgeon Successfully Completes Menaflex Surgery
HACKENSACK, N.J.--(HSMN NewsFeed)--ReGen Biologics (OTC: RGBO ) (“ReGen” or “the company”) reported that the first commercial surgery in the U.S. utilizing its Menaflex collagen meniscus implant was completed on Wednesday April 15, 2009.The surgery was performed at Jewish Hospital & St. Mary’s HealthCare in Louisville, Kentucky by David Caborn, M.D., for a patient who had a partial meniscectomy four years previously. Dr. Caborn commented on the procedure, “The Menaflex implant represents a much needed new treatment option for patients with meniscus deficiency. I am excited about the potential for the Menaflex procedure to decrease pain, improve function and decrease the reoperation rate in this patient population.”
Also commenting was Gerald E. Bisbee, Jr., Ph.D., Chairman and CEO of ReGen, “We are delighted that Dr. Caborn performed the first U.S. Menaflex procedure. He is a distinguished surgeon who is committed to meniscus preservation.”
Surgeons who have attended the ReGen surgical training program are listed on the Menaflex website (www.menaflex.com) to assist with patient awareness and education.
About Jewish Hospital & St. Mary’s HealthCare
Jewish Hospital & St. Mary’s HealthCare (JHSMH) was created when two of the region’s most well-established health systems – Jewish Hospital HealthCare Services and CARITAS Health Services – joined together in 2005. The merged company is a major regional health network that includes 71 health care facilities with more than 1,900 licensed beds, over 42,000 discharges and almost 100,000 emergency room visits annually. JHSMH provides a complete array of health care services in Kentucky and southern Indiana including: hospitals, behavioral health, assisted living, home health care, outpatient care, nursing home care, occupational health and rehab medicine. Visit www.jhsmh.org for more information.
About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen’s Menaflex™ collagen meniscus implant employs proprietary biological collagen scaffold technology to facilitate tissue growth, thereby reinforcing and repairing the damaged meniscus of the knee. The Menaflex device has been cleared for sale in Europe and other countries, and is marketed through ReGen’s European subsidiary, ReGen Biologics AG. The FDA cleared the Menaflex device for marketing in the United States in December 2008. Visit www.regenbio.com and www.menaflex.com for more information.
This press release contains forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on the current expectations and beliefs of ReGen management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including those discussed in the Risk Factors section of ReGen's 2008 annual report on Form 10-K and additional filings with the SEC. ReGen's filings with the SEC are available to the public at the Company's website at http://www.regenbio.com, from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.
Source: ReGen Biologics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
